ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Significance of the MONARCH 2 Findings for Abemaciclib in HR+/HER2- Breast Cancer

Peter Kaufman, MD
Published Online: 4:08 PM, Tue June 6, 2017

Peter Kaufman, MD, associate professor of Medicine, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, discusses the significance of the MONARCH 2 trial, which explored abemaciclib in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer who progressed on endocrine therapy during the 2017 ASCO Annual Meeting.
 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.